Navigation Links
Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
Date:11/4/2015

DUBLIN, Nov. 4, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO 

Under the terms of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and will fund phase 3 development of tavilermide. Mimetogen will additionally be entitled to receive potential milestone payments and royalties based on commercialization of the product.

Tavilermide is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye responsible for the maintenance of corneal nerves and epithelium. Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin, a naturally occurring component of the tear film, and works upstream prior to inflammation.

"Allergan is committed to leading in the development of novel therapies in eye care and dry eye disease," said David Nicholson, Executive Vice President and President, Global Brands Research and Development at Allergan. "Tavilermide brings a novel approach to treating the signs and symptoms of dry eye disease by enhancing the ocular tear film. If approved, tavilermide would provide another exciting new treatment option for patients suffering with dry eye and further strengthen our dry eye portfolio and pipeline."

"Mimetogen is excited to work together with Allergan, the recognized leader in developing effective therapies to treat dry eye disease," noted Garth Cumberlidge, PhD, Mimetogen President & CEO. "I am very proud of our Mimetogen colleagues who have worked very hard to develop tavilermide, and look forward to working with Allergan to advance this important development program for patients."

In a previously announced Phase 2 trial (Study Designation MIM-725) tavilermide demonstrated significant improvements in both signs and symptoms with 1% tavilermide versus placebo, together with strong safety, comfort and tolerability profiles. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.

"Dry eye disease continues to be an area where novel therapies are needed to improve the treatment of the disease, including the underlying cause of dry eye, for patients," said Rajesh K. Rajpal, MD, Medical Director and Founder, See Clearly Vision Group, Mclean, VA and Clinical Faculty, Georgetown University, Washington, DC.  "Tavilermide has shown the ability to improve patient-reported blurriness and poor vision with a positive comfort and tolerability profile in recent clinical studies. This development program is encouraging for the ophthalmology community seeking new therapies to better address this important area of patient treatment."

Dry Eye Disease
Dry eye disease can be caused by advanced age, contact lens wear, certain medications, eye diseases, other medical conditions or environmental factors. One type of dry eye is caused by decreased tear production due to inflammation. Without enough tears, the film protecting the eye can break down, creating dry spots on the cornea. Chronic dry eye is estimated to affect 25 million patients in the U.S.[1]

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

About Mimetogen Pharmaceuticals
Mimetogen Pharmaceuticals, Inc. is a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology, originally licensed from McGill University and the Lady Davis Institute for Medical Research in Montreal, has been developed with the support of VIMAC Milestone Medica, Ora, Medwell Capital, MSBi Valorisation, and iNovia Capital.

Allergan Forward-Looking Statements
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings having been filed under the "Allergan plc" or "Actavis plc" names) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

[1] Market Scope®, 2011 Report on the Global Market for Dry Eye Products; 2011, 1-148.

CONTACTS:     
Allergan:
Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558


'/>"/>
SOURCE Allergan plc
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg
2. Apollo Endosurgery Announces Acquisition of Obesity Intervention Division from Allergan, Inc.
3. Apollo Endosurgery Completes Acquisition of Allergan Inc.s Obesity Intervention Division
4. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
5. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
6. Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
7. Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergans False and Misleading Statements
8. Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergans False And Misleading Statements
9. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
10. Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders
11. Valeant Extends Offer To Acquire Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2019)... (PRWEB) , ... November 16, 2019 , ... International Splash ... the Tools and Apps category. , Srijan got nominated for its efforts at ... its commendable work for Estee Lauder under tools and apps category. The event was ...
(Date:11/16/2019)... N.C. (PRWEB) , ... November 15, 2019 , ... ... launch of its reconceptualized website http://www.medshift.com . The new site features ... medical practices and device developers navigate service offerings. , “The company has expanded ...
(Date:11/16/2019)... ... November 15, 2019 , ... MemoryCare.com , a ... the Best Memory Care Facilities in Columbus, Ohio. The guide identifies 21 memory ... , According to the Alzheimer’s Association , 5.6 million people age 65 ...
Breaking Medicine Technology:
(Date:11/16/2019)... VEGAS (PRWEB) , ... November 15, 2019 , ... ... seen before in the United States, access to cannabis via well-managed dispensaries becomes ... marijuana industry. Wise Business Plans, industry-leading online provider of state-of-the-art, online, custom cannabis ...
(Date:11/15/2019)... Md. (PRWEB) , ... November 15, 2019 , ... ... in and co-builds next-generation cybersecurity and data science companies with nation-state experienced technical ... winner of its second-annual DataTribe Challenge is Code Dx Inc ., based ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... linearity and calibration verification kit, specifically targeted for Roche cobas® and Roche ... evaluates a1-Antitrypsin (ATT), Complement C3 (C3), Complement C4 (C4), Immunoglobulin A (IGA), ...
(Date:11/14/2019)... ... ... winter just around the corner, parents want to make sure their children are nice and ... ones warm, during a car ride they can become dangerous, no matter how quick the ... to ensure maximum safety during a crash or sudden stop. While children may want to ...
(Date:11/12/2019)... ... November 12, 2019 , ... The quality of ... activation cycle times, extended contract negotiations and 80 percent of organizations still using ... operations that’s ripe for improvement. Following an overview of the challenges facing trial ...
Breaking Medicine News(10 mins):